↓ Skip to main content

Dove Medical Press

Article Metrics

Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy.

Overview of attention for article published in Vascular Health and Risk Management, January 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#29 of 364)
  • High Attention Score compared to outputs of the same age (86th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

blogs
1 blog
twitter
5 tweeters

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
53 Mendeley
Title
Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy.
Published in
Vascular Health and Risk Management, January 2015
DOI 10.2147/vhrm.s89842
Pubmed ID
Authors

Anne Blaes, Aamer Rehman, David Vock, Xianghuo Luo, Mark Menge, Douglas Yee, Emil Missov, Daniel Duprez

Abstract

Anthracycline chemotherapy remains an integral part of the care for curative intent chemotherapy in breast cancer and non-Hodgkin lymphoma patients. Better tools need to be identified to predict cardiac complications of anthracycline chemotherapy. We investigated the utility of high-sensitivity cardiac troponin T (hscTnT), N-terminal pro-B-type natriuretic peptide, cardiac troponin T and I, and creatine kinase (CK)-MB in cancer patients receiving anthracycline-based chemotherapy, in order to determine whether baseline levels or changes in these biomarkers may help predict the onset of congestive heart failure. Eighteen consecutive patients with a pathologic diagnosis of breast cancer or non-Hodgkin lymphoma were enrolled. The median dose of doxorubicin exposure was 240 mg/m(2) (range 240-400 mg/m(2)). After treatment with doxorubicin, the hscTnT increased to 19.1 pg/mL (P<0.001). CKMB and N-terminal pro-B-type natriuretic peptide levels increased to 1.1 ng/mL and 88.3 pg/mL, respectively (P=0.02). When subjects who had a decline in left ventricular ejection fraction (LVEF) by equilibrium radionuclide ventriculography were compared to those who did not have a change in LVEF, there was a suggestion that those subjects with an elevated baseline hscTnT were more likely to have a decline in LVEF (2.7 pg/mL and 0.1 pg/mL, respectively; P=0.07). Spearman correlation demonstrated that patients with higher baseline hscTnT and CKMB tended to have a greater decline in LVEF (Spearman correlation -0.54, 95% confidence interval -0.80 to -0.08 [P=0.02], and -0.49, 95% confidence interval -0.77 to -0.01 [P=0.04], respectively). Elevations in baseline hscTnT levels are suggestive of an oncology subgroup at high risk of developing cardiac complications from their chemotherapy. Early detection by oncologists with the use of baseline biomarkers may be clinically important in designing interventions to prevent serious anthracycline-based chemotherapy complications.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Tunisia 1 2%
Unknown 51 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 15%
Student > Master 8 15%
Other 7 13%
Student > Ph. D. Student 6 11%
Researcher 4 8%
Other 10 19%
Unknown 10 19%
Readers by discipline Count As %
Medicine and Dentistry 25 47%
Pharmacology, Toxicology and Pharmaceutical Science 4 8%
Psychology 2 4%
Computer Science 2 4%
Economics, Econometrics and Finance 1 2%
Other 4 8%
Unknown 15 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 December 2015.
All research outputs
#671,435
of 6,737,133 outputs
Outputs from Vascular Health and Risk Management
#29
of 364 outputs
Outputs of similar age
#37,346
of 277,262 outputs
Outputs of similar age from Vascular Health and Risk Management
#3
of 12 outputs
Altmetric has tracked 6,737,133 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 364 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,262 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.